multimmune GmbH

multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists'​ (Professor Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells. This makes this form of Hsp70 an excellent and broadly-applicable molecule on which to base the development of innovative therapeutics and diagnostics (theranostics).

Based on its discovery of membrane Hsp70, multimmune has succeeded in developing a powerful pipeline of mi-THERAPEUTICS (tx). ENKASTIM allows, for the first time, a unique and specific activation of human natural killer (NK) cells which are programmed to recognise and kill cancers expressing membrane Hsp70 via the release of a cytotoxic molecule called granzyme B. These cells destroy tumors and metastases that are invisible to the cell killing (cytolytic) consequences of more conventional T cell-based immunotherapies.

Hsp70-expressing tumors can also be targeted using a unique monoclonal antibody which can detect the membrane form of Hsp70 (mi-TUMEXtx) and a serine protease (granzyme B, mi-APO) which can selectively kill cancer cells expressing the membrane form of Hsp70.

multimmune's lead mi-DIAGNOSTICS (dx) candidates are a patented monoclonal antibody for detecting the presence of tumors expressing the membrane form of Hsp70, and which also forms the basis to a patented enzyme immunoassay for the detection of lipid-associated Hsp70 in the peripheral circulation.

multimmune's mi-IMAGING (im) platform is based on the product candidate mi-TUMEXim - membrane Hsp70-specific monoclonal antibody which detect the membrane form of Hsp70 which is selectively expressed on tumor cells.